Nurami Medical, a medical nanofiber technology company, has raised up to $6 million in series B funding to finance ongoing clinical trials for ArtiFascia. Funding will also be used for the regulatory approval process for the US Food and Drug Administration (FDA) and CE. Funding was led by Almeda Ventures, a health-tech focused public research and development partnership.
ArtifFacia is a synthetic dural graft, which is intended to help the healing and repair of the dura after cranial neurosurgery. Nurami claims it does this by boosting dura regeneration, preventing the leakage of cerebral-spinal fluid (CSF), and protecting the brain and the central nervous system.
The clinical trial for ArtiFascia will consist of 90 subjects, 13 of which have already been implanted with an ArtiFascia graft. This trial will occur in European medical centers, composed of a controlled, blind study.
This is Nurami’s first product, although they are currently developing other products for the healing and regeneration of soft tissue. They were formed in 2014 Dr. Amir Bahar, Nora Nseir Manassa and NGT3VC, a venture capital fund. Their technology consists of biodegradable, synthetic nanofibers, which have sealing properties for soft tissue.
Hannoch Marksheid, co-CEO of Nurami, stated, “Our first product, ArtiFascia, offers clear clinical and economic benefits to the 600,000 neurosurgeries performed annually, representing a $1 billion market with an annual growth rate of 6%.”
